Skip to content
Subscriber Only
Business

Ackman Defends Valeant’s Drug Development on Investor Call

  • Investor says Valeant’s R&D programs are ‘mischaracterized’
  • Two drugs up for approval, research spending lags rivals
Video player cover image

Why Ackman Plans to Maintain Bet Against Herbalife

Billionaire investor Bill Ackman defended Valeant Pharmaceuticals International Inc.’s research and development program, citing two drugs making their way toward the market and another just cleared.

“People have mischaracterized Valeant’s R&D programs,” Ackman, whose Pershing Square Capital Management LP is one of the drugmaker’s biggest holders, said Wednesday on a conference call with investors. “This company has one of the most productive R&D programs of any pharmaceutical company in the country.”